MarginsXMarginsX
Home › Data Desk › Oncology

Oncology

Automated articles on Oncology, built every day from SEC filings, prices and our own datasets.

All topics · Dilution · Offerings · Convertible notes · FDA approval · Licensing and milestone payments · At-the-market offering · Delistings · Mergers and acquisitions · Restaurants · Casinos · Foreign private issuer · Material weakness · Early-stage clinical trials · Oncology · FDA setbacks · Reverse split · Private placement (PIPE) · Warrants and inducements · Biofuels and renewable natural gas · Insider buying · Debt financing · Divestitures · Solar · Artificial intelligence · Equity line of credit · Late-stage clinical trials · Daily feature · Going-concern doubt · Week ahead · Customer concentration · Late filings · Weekly roundups · Rates and the dollar · Banking · Quarterly results · Dual-class shares · Inflation and interest rates · Share buybacks · AI data centers · Executive turnover · GPUs and accelerators · Big movers · IPO · Public offerings · SPAC · China exposure · Convertible preferred stock · Natural gas and LNG · Cryptocurrency · Bankruptcy · Tobacco and vaping · Related-party loans · Nasdaq deficiency notice · Payments and fintech · Alcoholic beverages · Oil and gas production · Delisting · Aerospace and aviation · Tariffs · Medical devices · 13G holders · Carbon and clean energy credits · Semiconductors · Cannabis · Electric vehicles · Name or ticker change · Aesthetics and dermatology · Pet products · Stablecoins · Critical minerals · Gold mining · Mineral exploration · Auditor changes · Drones · Cell and gene therapy · Defense and military · Exchange listing notices · OTC quotation · Battery energy storage · Authorized share increase · 13D stakes · Robotics · Market wrap · Dividend payments · Spin-offs · Carbon capture · Impairment charges · Firearms and ammunition · Reverse merger · Securities class actions · Generative AI · Layoffs and restructuring · Asset management and BDCs · Hydrogen and fuel cells · Joint ventures · REITs and real estate · Reverse splits · Data centers · Backlog and contracted revenue · Trucking and logistics · Agriculture · Wind power · Video games and esports · War and geopolitical risk · Insurance carriers · Medicare and Medicaid reimbursement

Vir Biotechnology Inc. puts a 424B5 prospectus supplement on file

On Nov 16, 2026, Vir Biotechnology Inc. (VIR) filed a 424B5: a prospectus supplement for a sale from its shelf. (SEC EDGAR, 424B5, Nov 16, 2026)

November 16, 2026 · data as of 2026-11-16

Medicus Pharma Ltd. files a 424B5 prospectus supplement

Medicus Pharma Ltd. (MDCX) filed a 424B5 on Nov 16, 2026, a prospectus supplement for a sale from its shelf. (SEC EDGAR, 424B5, Nov 16, 2026)

November 16, 2026 · data as of 2026-11-16

Rezolute Inc. files a 424B5 prospectus supplement

Rezolute Inc. (RZLT) filed a 424B5 on Nov 16, 2026, a prospectus supplement for a sale from its shelf. (SEC EDGAR, 424B5, Nov 16, 2026)

November 16, 2026 · data as of 2026-11-16

Context Therapeutics Inc.'s 10-Q carries going-concern doubt

In its 10-Q, filed Nov 10, 2026, Context Therapeutics Inc. (CNTX) disclosed substantial doubt that it can carry on as a going concern. (SEC EDGAR, 10-Q, Nov 10, 2026)

November 14, 2026 · data as of 2026-11-10

State Street Corp passes 5.0% of Recursion Pharmaceuticals Inc.

In a Schedule 13G filed Nov 10, 2026, State Street Corp reported 30.0 million shares of Recursion Pharmaceuticals Inc. (RXRX) as of Sep 30, 2026, 5.6% of the class. (SEC EDGAR, SCHEDULE 13G, Nov 10, 2026)

November 14, 2026 · data as of 2026-11-10

Starling Oncology Inc.: Form 25-NSE filed to end a listing

On Nov 13, 2026 a Form 25-NSE was filed to take a class of Starling Oncology Inc. (STLN) securities off an exchange. (SEC EDGAR, 25-NSE, Nov 13, 2026)

November 14, 2026 · data as of 2026-11-13

Lyell Immunopharma Inc. puts an S-3 shelf registration on file

On Nov 13, 2026, Lyell Immunopharma Inc. (LYEL) filed an S-3: a shelf registration for securities it can sell later. (SEC EDGAR, S-3, Nov 13, 2026)

November 14, 2026 · data as of 2026-11-13

Vir Biotechnology Inc. files for an at-the-market share sale

Vir Biotechnology Inc. (VIR) filed a 424B5 on Nov 12, 2026 whose text describes an at-the-market offering, shares sold into the market over time through a sales agent. (SEC EDGAR, 424B5, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

Eikon Therapeutics Inc. has about 4.2 months of cash at its recent burn

The 10-Q that Eikon Therapeutics Inc. (EIKN) filed on Nov 12, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

Olema Oncology Inc. reports $47.5M of cash, about 3.2 months at its recent burn

Olema Oncology Inc. (OLMA) filed its 10-Q on Nov 10, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

November 14, 2026 · data as of 2026-11-10

Relmada Therapeutics Inc. reports $5.7M of cash, about 1.3 months at its recent burn

Relmada Therapeutics Inc. (RLMD) filed its 10-Q on Nov 12, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

Aura Biosciences Inc. reports $41.7M of cash, about 4.6 months at its recent burn

Aura Biosciences Inc. (AURA) filed its 10-Q on Nov 9, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 9, 2026)

November 14, 2026 · data as of 2026-11-09

Aktis Oncology Inc. revenue rises 147.3% in the quarter to Sep 30, 2026

Aktis Oncology Inc. (AKTS) filed its 10-Q on Nov 12, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

Freenome Inc. revenue rises 17628.4% in the quarter to Sep 30, 2026

Freenome Inc. (FRNM) filed its 10-Q on Nov 12, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

November 14, 2026 · data as of 2026-11-12

Zymeworks Inc. grows revenue 828.7% in the quarter to Sep 30, 2026

The 10-Q that Zymeworks Inc. (ZYME) filed on Nov 9, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 9, 2026)

November 14, 2026 · data as of 2026-11-09

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Follow topics in MarginsX